Johnson & Johnson
JNJHealthcareNASDAQDrug Manufacturers - General · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Johnson & Johnson focuses on Drug Manufacturers - General services and products. Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. The company carries a $635.07B market cap, placing it firmly in the mega-cap category. It operates in two segments, Innovative Medicine and MedTech.
Market Cap
$635.07B
Beta
0.21
P/E (TTM)
40.03
P/E (Fwd)
22.71
EPS (TTM)
$6.59
EPS (Fwd)
$11.62
ROE
20.0%
ROA
8.5%
Cash
$17.23B
Total Debt
$44.65B
Free CF
$18.50B
52W Change
38.6%
Annual Financials
Cash vs Debt
Where JNJ stands vs its 150-day and 200-day moving averages
As of the October 14, 2026 close, JNJ finished 0.69% above its 150-day moving average ($246.90) and 2.92% above its 200-day moving average ($241.55). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is JNJ overbought or oversold?
At the October 14, 2026 close, JNJ's RSI(14) was 30.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, JNJ has $17.23B in cash with $44.65B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $18.50B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 20.0% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $79.99B to $94.19B.
JNJ's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing JNJ.